NCT01797848View on ClinicalTrials.gov

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Hepatitis C
Interventions
DRUG

Peginterferon alfa 2a

DRUG

Ribavirin

DRUG

Placebo matching Daclatasvir

DRUG

Daclatasvir

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY